China High Quality Valerophenone Suppliers – 99% Apixaban CAS 503612-47-3 – Baoran

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We support our purchasers with ideal high-quality merchandise and significant level company. Becoming the specialist manufacturer in this sector, we now have received loaded practical encounter in producing and managing for 110-91-8, Cas 10124-56-8, Ethyl Methacrylate Ema, All products come with good quality and perfect after-sales services. Market-oriented and customer-oriented are what we have been being after. Sincerely look forward to Win-Win cooperation !
China High Quality Valerophenone Suppliers – 99% Apixaban CAS 503612-47-3 – Baoran Detail:

Specification

ITEM

STANDARD

Appearance

White to off-white solid

Purity

≥ 99%

Application

On April 26, 2007, Bristol-Myers Squibb and Pfizer announced a joint development of the new oral anticoagulant apixaban owned by Bristol-Myers Squibb as an upgraded alternative to warfarin.
In May 2011, apixaban was the first to be approved for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery in 27 EU countries, Iceland and Norway.
On November 20, 2012, the European Commission approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
The Canadian Food and Drug Administration, Japan, and the U.S. Food and Drug Administration subsequently approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
On April 12, 2013, ELIQUIS (Apixaban), was officially announced on the market in China. Apixaban is a novel oral factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its launch provides a safe and effective new option for anticoagulation after orthopaedic surgery in clinical practice, and brings good news to Chinese patients undergoing elective hip/knee replacement.
Clinical studies have confirmed that compared with 40 mg subcutaneous injection of enoxaparin once a day, 2.5 mg of ELIQUIS (Apixaban) orally twice a day is more effective in preventing venous thromboembolic events after hip or knee replacement surgery , and does not increase the risk of bleeding.

Packing & Storage

100g/500g/1kg/25kg or as request;
Stored at room temperature and airtight.


Product detail pictures:

China High Quality Valerophenone Suppliers –  99% Apixaban CAS 503612-47-3 – Baoran detail pictures


Related Product Guide:

We consistently execute our spirit of ''Innovation bringing progress, Highly-quality ensuring subsistence, Administration advertising and marketing gain, Credit history attracting buyers for China High Quality Valerophenone Suppliers – 99% Apixaban CAS 503612-47-3 – Baoran, The product will supply to all over the world, such as: Marseille, Lisbon, Czech Republic, In order to make more people know our products and to enlarge our market, we have devoted a lot of attention to technical innovations and improvement, as well as replacement of equipment. Last but not the least, we also pay more attention to training our managerial personnel, technicians and workers in planned way.
  • Sales manager is very enthusiastic and professional, gave us a great concessions and product quality is very good,thank you very much!
    5 Stars By Myrna from Hamburg - 2018.11.11 19:52
    The goods are very perfect and the company sales manager is warmful, we will come to this company to purchase next time.
    5 Stars By Chloe from Paraguay - 2017.11.29 11:09
    Write your message here and send it to us

    Related Products